

PATENT
USSN 09/843,676
Docket 002943US; 018/181c

CLAIM AMENDMENTS

1 to 20. CANCELLED

21. *(Currently amended)* ~~A polypeptide containing at least 10~~ An isolated polypeptide that induces anti-hTERT specific antibody, consisting of 10 or more consecutive amino acids of the sequence provided in SEQ. ID NO:225.
22. *(Currently amended)* The polypeptide of claim 21, containing an amino acid sequence selected from ~~the group consisting of~~ SEQ. ID NO:112, SEQ. ID NO:113, SEQ. ID NO:114, SEQ. ID NO:115, SEQ. ID NO:116, and SEQ. ID NO:117.
23. *(Previously presented)* The polypeptide of claim 21, which does not retain the telomerase catalytic activity of native human telomerase reverse transcriptase.
24. *(Previously presented)* A pharmaceutical composition comprising the polypeptide of claim 21 and a pharmaceutically acceptable carrier.
25. *(Currently amended)* ~~An immunogenic composition comprising the polypeptide of claim 21 and an adjuvant~~
that induces anti-hTERT specific antibody, comprising a peptide and an adjuvant, wherein the peptide consists of 10 or more consecutive amino acids of SEQ. ID NO:225.
26. *(Currently amended)* The composition of claim 25, wherein the adjuvant is selected from the ~~group consisting of~~ Freund's adjuvant, an mineral gel, aluminum hydroxide, lysolecithin, pluronic polyol, a polyanion, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum.
27. *(Withdrawn)* *(Currently amended)* A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the ~~polypeptide of claim 21~~ composition of claim 25.
28. *(Withdrawn)* The method of claim 27, further comprising assessing whether telomerase-specific antibody is produced as a result of the administration.

PATENT
USSN 09/843,676
Docket 002943US; 018/181c

29. *(Currently amended)* An immunogenic composition comprising ~~a polypeptide consisting essentially of 5 to 10 consecutive amino acids of the sequence provided in SEQ. ID NO:225, and an adjuvant~~
that induces anti-hTRT specific antibody, comprising a peptide and an adjuvant, wherein the peptide consists of 5 to 10 consecutive amino acids of SEQ. ID NO:225.
30. *(Currently amended)* The composition of claim 29, wherein the adjuvant is selected from the group consisting of Freund's adjuvant, an mineral gel, aluminum hydroxide, lysolecithin pluronic polyol, a polyanion, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum.
31. *(Withdrawn) (Currently amended)* A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject ~~a polypeptide consisting essentially of 5 to 10 consecutive amino acids of the sequence provided in SEQ. ID NO:225~~ the composition of claim 29.
32. *(Withdrawn)* The method of claim 27, further comprising assessing whether telomerase-specific antibody is produced as a result of the administration.
33. *(New)* The polypeptide of claim 21, produced by recombinant expression.
34. *(New)* The polypeptide of claim 21, produced by chemical synthesis.
35. *(New)* A chimeric molecule comprising:
a polypeptide that consists of 10 or more consecutive amino acids of SEQ. ID NO:225, and
an immunogenic second protein,
wherein the polypeptide is fused to the second protein so as to form a chimeric molecule that induces anti-hTRT specific antibody.
36. *(New)* The chimeric protein of claim 35, wherein the second protein is keyhole limpet hemocyanin.
37. *(New)* An immunogenic composition comprising the chimeric protein of claim 35, and an adjuvant.

PATENT
USSN 09/843,676
Docket 002943US; 018/181c

38. (New) A chimeric molecule comprising:
a polypeptide that consists of 5 to 10 consecutive amino acids of SEQ. ID NO:225, and
an immunogenic second protein,
wherein the polypeptide is fused to the second protein so as to form a chimeric molecule
that induces anti-hTERT specific antibody.
39. (New) The chimeric protein of claim 38, wherein the second protein is keyhole limpet
hemocyanin.
40. (New) An immunogenic composition comprising the chimeric protein of claim 38, and an
adjuvant.